273 related articles for article (PubMed ID: 11376431)
1. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
Burke TR; Yao ZJ; Liu DG; Voigt J; Gao Y
Biopolymers; 2001; 60(1):32-44. PubMed ID: 11376431
[TBL] [Abstract][Full Text] [Related]
2. Phosphotyrosyl mimetics in the development of signal transduction inhibitors.
Burke TR; Lee K
Acc Chem Res; 2003 Jun; 36(6):426-33. PubMed ID: 12809529
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides.
Yao ZJ; Lee K; Burke TR
Methods Mol Biol; 2005; 298():91-103. PubMed ID: 16044542
[TBL] [Abstract][Full Text] [Related]
4. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
[TBL] [Abstract][Full Text] [Related]
5. Src homology-2 domains: structure, mechanisms, and drug discovery.
Sawyer TK
Biopolymers; 1998; 47(3):243-61. PubMed ID: 9817027
[TBL] [Abstract][Full Text] [Related]
6. Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
Lee K; Zhang M; Liu H; Yang D; Burke TR
J Med Chem; 2003 Jun; 46(13):2621-30. PubMed ID: 12801226
[TBL] [Abstract][Full Text] [Related]
7. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery.
Burke TR; Zhang ZY
Biopolymers; 1998; 47(3):225-41. PubMed ID: 9817026
[TBL] [Abstract][Full Text] [Related]
8. 4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.
Burke TR; Ye B; Akamatsu M; Ford H; Yan X; Kole HK; Wolf G; Shoelson SE; Roller PP
J Med Chem; 1996 Mar; 39(5):1021-7. PubMed ID: 8676336
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.
Combs AP; Yue EW; Bower M; Ala PJ; Wayland B; Douty B; Takvorian A; Polam P; Wasserman Z; Zhu W; Crawley ML; Pruitt J; Sparks R; Glass B; Modi D; McLaughlin E; Bostrom L; Li M; Galya L; Blom K; Hillman M; Gonneville L; Reid BG; Wei M; Becker-Pasha M; Klabe R; Huber R; Li Y; Hollis G; Burn TC; Wynn R; Liu P; Metcalf B
J Med Chem; 2005 Oct; 48(21):6544-8. PubMed ID: 16220970
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic.
Burke TR
Curr Top Med Chem; 2006; 6(14):1465-71. PubMed ID: 16918462
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK
Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680
[TBL] [Abstract][Full Text] [Related]
14. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain.
Liu WQ; Vidal M; Gresh N; Roques BP; Garbay C
J Med Chem; 1999 Sep; 42(18):3737-41. PubMed ID: 10479306
[TBL] [Abstract][Full Text] [Related]
15. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
Burke TR; Barchi JJ; George C; Wolf G; Shoelson SE; Yan X
J Med Chem; 1995 Apr; 38(8):1386-96. PubMed ID: 7537333
[TBL] [Abstract][Full Text] [Related]
16. SH2 and PTB domains in tyrosine kinase signaling.
Schlessinger J; Lemmon MA
Sci STKE; 2003 Jul; 2003(191):RE12. PubMed ID: 12865499
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
18. Peptidyl aldehydes as reversible covalent inhibitors of SRC homology 2 domains.
Park J; Fu H; Pei D
Biochemistry; 2003 May; 42(17):5159-67. PubMed ID: 12718560
[TBL] [Abstract][Full Text] [Related]
19. The crystal structures of the SH2 domain of p56lck complexed with two phosphonopeptides suggest a gated peptide binding site.
Mikol V; Baumann G; Keller TH; Manning U; Zurini MG
J Mol Biol; 1995 Feb; 246(2):344-55. PubMed ID: 7532720
[TBL] [Abstract][Full Text] [Related]
20. CH/pi hydrogen bonds determine the selectivity of the Src homology 2 domain to tyrosine phosphotyrosyl peptides: an ab initio fragment molecular orbital study.
Ozawa T; Okazaki K
J Comput Chem; 2008 Dec; 29(16):2656-66. PubMed ID: 18484636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
